Canada Approves Study of Reovirus for Treating Prostate Cancer

Oncolytics Biotech Inc.announced it has received approval from Health
Canada to initiate a clinical study to evaluate the efficacy of Reolysin®, a formulation of the reovirus, for the treatment of T2 prostate cancer.

"We are very excited to be given approval to enter our first clinical
study with efficacy as a primary endpoint," said Dr. Brad Thompson.

The company said 45 men will be enrolled in the trial at three Canadian centers to evaluate the efficacy of intra-tumoral administration of Reolysin® for treatment of cancer that is restricted to the prostate gland.

Patients will receive a single injection and will be monitored for approximately three weeks, at which time the prostate may be surgically removed.

Oncolytics said its researchers have demonstrated that the reovirus is
able to selectively kill cancer cells and, in vitro, kill human cancer cells
derived from many types of cancer including prostate cancer.

Other Sources: Oncolytics Biotech